Eric Hughes joined Novartis in 2015 and leads the Immunology and Dermatology (I&D) Unit. He and his team are responsible for the clinical development and regulatory approvals of Cosentyx® and a number of innovative treatments within the Unit.
Prior to joining Novartis, Eric worked for Bristol-Myers Squibb (BMS) Company for five years, most recently as Vice President and Head of Specialty Discovery Medicine, Exploratory Clinical and Translational Research. While at BMS, Eric led the simultaneous approval of two compounds, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir), and had extensive experience working with regulatory agencies around the world. He has broad experience in the industry, previously working for Schering-Plough and Merck Research Laboratories to design and execute Phase 1 through Phase 3 studies. Eric also has a track record of strong collaboration with key opinion leaders and patient advocacy groups.
Eric is a licensed physician with specialty training in infectious diseases who received his medical degree and doctoral degree in immunology from Yale University and has a B.S. from Haverford College.